Melanotan II (MT-2) — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Melanotan II Dosing Guide: Loading Dose, Maintenance & Side Effects (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Melanotan 2 (MT-2) Peptide Guide: Dosing, Reconstitution & Safety (2026) Protocol / Research Dosing Guide Melanotan 2 (MT-2) Peptide Guide: Dosing, Reconstitution & Safety (2026) An educational research guide to Melanotan 2 (MT-2): how it works, common loading and maintenance schedules used in research planning, reconstitution math, side effects, and how it compares to PT-141 and afamelanotide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code SAVE10 Copy code SAVE10 Verified Supplier Verified Supplier Ventra Sciences Melanotan 2 Supply View Ventra Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Melanotan 2 Comparisons Related Protocols Blood Tests FAQ References Melanotan 2 Quick Start Melanotan 2 (also written MT-2, MT-II, or melanotan ii) is a lab-made peptide. It was first developed at the University of Arizona in the 1980s and 1990s.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (11) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, monitoring_reference, mechanism

Findings (174) · awaiting review (138)

mechanism · pending

Different mechanism, different evidence base.

dosing · pending

Loading Phase - Daily Dosing Stage Assessment Days Days 1-3 Dose 100-250 mcg daily Notes Used to check how well nausea and flushing are tolerated.

dosing · pending

Peptide Vials A 10 mg vial provides about 20 doses at 500 mcg per day.

dosing · pending

Stage Low loading Days Days 4-14 Dose 250-500 mcg daily Notes Step up only if side effects stay manageable.

dosing · pending

Stage Standard loading Days Weeks 3-6 Dose 500-1000 mcg daily Notes Continued until target pigment is reached.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code SAVE10 Copy code SAVE10 Verified Supplier Verified Supplier Ventra Sciences Melanotan 2 Supply View Ventra Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Melanotan 2 Comparisons Related Protocols Blood Tests FAQ References Melanotan 2 Quick Start Melanotan 2 (also written MT-2, MT-II, or melanotan ii) is a lab-made peptide.

safety · pending

nd lasts longer than the natural one, which is why it has bigger effects but also more side effects.

dosing · pending

Most research workflows use a daily loading phase followed by a weekly maintenance dose.

dosing · pending

The most common vial size is 10 mg, and the most common route is subcutaneous (SubQ) injection.

dosing · pending

Use this page for dose steps, timing, vial mixing, and storage.

safety · pending

See the Melanotan II safety guide on Peptide Advisors.

dosing · pending

Route Subcutaneous (SubQ) injection is the most studied route.

dosing · pending

The unit math depends on how much BAC water you mix with the 10 mg vial.

dosing · pending

Loading A common research framework starts at 100-250 mcg daily and escalates to 500-1000 mcg as nausea tolerance improves.

dosing · pending

Maintenance After loading, many users drop to 1-2 doses per week to hold pigmentation.

regulatory · pending

Melanotan 2 is not FDA-approved and is sold for research use only.

dosing · pending

Melanotan 2 Dosing Protocol & Schedule There is no FDA-approved dose for Melanotan 2.

dosing · pending

Loading is daily dosing to build pigment.

dosing · pending

Maintenance is one or two doses per week to hold it.

dosing · pending

Nausea is the main reason people slow down or pause dose increases.

dosing · pending

Melanotan 2 Dosing Framework Pick the phase you are researching to see the typical dose and timing notes.

dosing · pending

Loading Phase Maintenance ED Trial Dosing (Context Only) Daily dosing used to build pigmentation during the first 4-6 weeks.

dosing · pending

Stage Days Dose Notes Assessment Days 1-3 100-250 mcg daily Used to check how well nausea and flushing are tolerated.

dosing · pending

Low loading Days 4-14 250-500 mcg daily Step up only if side effects stay manageable.

dosing · pending

Standard loading Weeks 3-6 500-1000 mcg daily Continued until target pigment is reached.

dosing · pending

Bedtime dosing is commonly used so peak nausea happens during sleep.

dosing · pending

Skin type matters Lighter skin types (Fitzpatrick I-II) usually see changes sooner and at lower doses.

dosing · pending

Lower-frequency dosing used to hold pigment once loading is finished.

dosing · pending

Maintenance Dosing Phase Standard maintenance Frequency 1-2x per week Dose 500-1000 mcg Notes Used to maintain pigment after loading ends.

dosing · pending

Phase Light maintenance Frequency 1x per week or less Dose 250-500 mcg Notes Common when pigment is already strong and UV exposure is regular.

dosing · pending

Phase Frequency Dose Notes Standard maintenance 1-2x per week 500-1000 mcg Used to maintain pigment after loading ends.

dosing · pending

Light maintenance 1x per week or less 250-500 mcg Common when pigment is already strong and UV exposure is regular.

dosing · pending

Higher per-dose levels used in early erectile-dysfunction studies.

dosing · pending

Trial-Level Dosing Used in ED Research Context ED trial dose Dose 0.025 mg/kg (about 1.75 mg at 70 kg / 154 lb) Notes Used in Phase II ED studies.

dosing · pending

Caused more nausea than typical tanning doses.

dosing · pending

Context Community low-dose context Dose 500 mcg to 1 mg Notes Reported by users seeking sexual-function effects with less GI burden.

dosing · pending

Context Dose Notes ED trial dose 0.025 mg/kg (about 1.75 mg at 70 kg / 154 lb) Used in Phase II ED studies.

dosing · pending

Community low-dose context 500 mcg to 1 mg Reported by users seeking sexual-funct

dosing · pending

They are not dosing recommendations.

Processing

Processed into 26 searchable sections.